Metabolic shares suspended

By Ruth Beran
Friday, 10 June, 2005

Melbourne based Metabolic Pharmaceuticals (ASX:MBP) has suspended its shares from the ASX's official quotation in the lead-up to an announcement.

This follows a trading halt on June 8, and a recent clarification by the company of a previously announced Phase IIb trial of its anti-obesity drug AOD9604 to determine optimal dosage.

Babies of stressed mothers likely to get their teeth earlier

Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...

Customised immune cells used to fight brain cancer

Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...

Elevated blood protein levels predict mortality

Proteins that play key roles in the development of diseases such as cancer and inflammation may...

Content from other channels on our network

Vaxxas secures TGA licence to manufacture vaccine patch technology

DroneShield nabs another European military contract

Daikin Australia opens new Sydney factory

AR3 to be first to process rare earths at ANSTO's new pilot facility

Defence Trailblazer funding manufacturing to help Defence and industry transition to clean energy

Four food safety tips for the silly season

Santa creates a spike in Australia's milk demand

Spicing up the festive season with Australian bushfood flavours

Kraft Heinz appoints Steve Cahillane as CEO

Irish drinks manufacturer takes its supply chain to the next level

Sustainability in 2026: what's next for Australian businesses?

How Australia can increase its circularity rate

$25m grant supports cleaner cement production

Bürkert team to take on sustainability strategies

ASC certifies NT barramundi farm